LLY Technical Analysis

As of date:	10/3/2023
LLY stock price:	525.19
LLY 50 DMA:	534.29
LLY 200 DMA:	420.47
LLY MACD (200-50):	-113.82
LLY RSI:	7.98

Extremely Overbought
	7.98
Extremely Oversold

Also see:
LLY Market Cap History
LLY Shares Outstanding History
LLY YTD Return

Predict charts, win cash @ chartsweeps.com

Quotes delayed 20 minutes

Free LLY Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

LNTH Makes Bullish Cross Above Critical Moving Average
1 hour, 4 minutes ago

Tile Shop Holdings (TTSH) Shares Cross Below 200 DMA
1 hour, 6 minutes ago

Advanced Energy Industries (AEIS) Shares Cross Below 200 DMA
1 hour, 14 minutes ago

IPAR Crosses Below Key Moving Average Level
1 hour, 19 minutes ago

Notable Two Hundred Day Moving Average Cross - ORLY
1 hour, 22 minutes ago

Invesco Leisure and Entertainment Getting Very Oversold
1 hour, 24 minutes ago

Notable Two Hundred Day Moving Average Cross - PX
1 hour, 25 minutes ago

Shares of IXG Now Oversold
1 hour, 25 minutes ago

PHB Crowded With Sellers
1 hour, 25 minutes ago

iShares MSCI Mexico (EWW) Enters Oversold Territory
1 hour, 26 minutes ago

ITOT Makes Notable Cross Below Critical Moving Average
1 hour, 26 minutes ago

HYBB Crosses Critical Technical Indicator
1 hour, 26 minutes ago

HYS Getting Very Oversold
1 hour, 27 minutes ago

HYDW Enters Oversold Territory
1 hour, 27 minutes ago

RBC Bearings Breaks Below 200-Day Moving Average - Notable for RBCP
1 hour, 27 minutes ago

More Technical Analysis News

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

When researching a stock like Eli Lilly , many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from LLY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for LLY stock — the real life supply and demand for the stock over time — and examines that data in different ways.

10 Most Oversold S&P 500 Stocks

10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying

10 ETFs With Most Upside To Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active S&P Call & Put Options

Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Eli Lilly (LLY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

MCK Technical Analysis
MDT Technical Analysis
MMM Technical Analysis
MOH Technical Analysis
MRK Technical Analysis
MRNA Technical Analysis
OGN Technical Analysis
PFE Technical Analysis
PODD Technical Analysis
REGN Technical Analysis
More Healthcare companies »

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.

LLY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2023, All Rights Reserved